Recent therapeutic advances in urothelial carcinoma : A paradigm shift in disease management
Bellmunt, J. (Department of Medical Oncology. Beth Israel Deaconess Medical Center and IMIM-PSMAR Lab. Harvard Medical School)
Valderrama, B.P. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Puente, J. (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos)
Grande, Enrique (MD Anderson Cancer Center Madrid)
Bolós, M.V. (Pfizer)
Laínez, Nuria (Hospital Universitario de Navarra)
Vázquez, S. (Hospital Universitario Lucus Augusti (Lugo))
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau)
Climent, Miguel Ángel (Department of Medical Oncology. Valencia Institute of Oncology Foundation)
Garcia del Muro, Xavier (Institut d'Investigació Biomèdica de Bellvitge)
Arranz Alija, Jose Ángel (Hospital General Universitario Gregorio Marañón)
Durán, Ignacio (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria))
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	Management of first-line advanced urothelial carcinoma (UC) has consisted during the past three decades in the administration of platinum-based chemotherapy followed by observation. Despite moderate to high response rates to first-line treatment, most patients will relapse shortly after and the outcomes with subsequent therapies are poor with 5-year overall survival rates of 5% in the pre-immunotherapy era. Nonetheless, recent therapeutic developments including the paradigm shift of first-line maintenance therapy with avelumab after response or stabilization on platinum-based chemotherapy, along with the incorporation of new drug classes in further lines of treatment such as antibody drug-conjugates and fibroblast growth factor receptor inhibitors have reshaped the field leading to better outcomes in this patient population. This article reviews the current state of the art with an overview on UC management, recent advances, and the upcoming strategies currently in development in advanced UC with an insight into the biology of this disease.
Note:	Altres ajuts: Pfizer.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	Urothelial carcinoma (UC) ; Bladder cancer ; Platinum-based chemotherapy ; Checkpoint inhibitors (CPIs) ; Avelumab ; Switch maintenance ; Antibody drug-conjugate (ADC)
Published in:	Critical Reviews in Oncology/Hematology, Vol. 174 (june 2022) , p. 103683, ISSN 1879-0461

DOI: 10.1016/j.critrevonc.2022.103683
PMID: 35439541

16 p, 2.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles